Viva Biotech Holdings (01873)
| Director | From | To | Position(s) | Release Date / Document Links | Reason for Change |
|---|---|---|---|---|---|
| Chau Anita Hing Ling | 10-Jul-18 | CoSec | |||
| Fei Xiaoyu | 10-Jul-18 | CoSec | |||
| Fu Lei | 14-Apr-19 | INED | |||
| Fu Lei | 14-Apr-18 | INED | |||
| Hua Feng Mao | 03-Jul-18 | 30-Jun-21 | ED | ||
| Hua Fengmao | 29-Apr-21 | 30-Jun-21 | ED | ||
| 03-Jul-18 | 29-Apr-21 | FD | |||
| Li Cathy Xiangrong | 14-Apr-19 | INED | |||
| Li Xiang Rong | 14-Apr-18 | INED | |||
| Mao Cheney Chen | 03-Jul-18 | Ch, CEO | |||
| Mao Jun | 03-Jul-18 | 03-Nov-20 | Co-Fdr, NED | ||
| Ren De Lin | 03-Jul-18 | ED | |||
| Ren Delin | 01-Dec-23 | ED | |||
| 03-Jul-18 | 01-Dec-23 | Pres | The change in executive responsibilities will enable Mr. Ren to focus more of his attention to leading the Group’s CRO and drug discovery businesses. | ||
| Sun Yanyan | 30-Mar-20 | 14-Nov-22 | NED | To devote more time to pursue her other business engagements | |
| Wang Hai Guang | 14-Apr-18 | INED | |||
| Wang Haiguang | 14-Apr-19 | INED | |||
| 27-Mar-25 | MbNC | Mr. WANG Haiguang ceases to be a member of the nomination committee of the Board to enhance the corporate governance of the Company and to fulfill the new gender diversity requirement of the nomination committee under the amended CG Code and the Listing Rules. | |||
| Wang Stephen Hui | 18-Jan-24 | 16-Feb-26 | NED | Mr. Wang resigned in order to devote more time to pursue his other personal and business engagements. | |
| Wang Zheren | 29-Apr-21 | 27-Sep-24 | CFO | ||
| 27-Sep-24 | Co-CFO | Mr. Wang has tendered his resignation from the role of Co-Chief Financial Officer to focus more on leading the financial management and strategic development of Viva Shanghai. | |||
| Wu John Jiong | 03-Jul-18 | 30-Mar-20 | NED | ||
| Wu Ying | 07-Sep-09 | ED | |||
| Wu Yu Ting | 14-Nov-22 | Non-executive Director | |||
| Wu Yuting | 14-Nov-22 | NED | |||
| Xiong Wei | 01-Dec-23 | CFO |